How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?

Platelets

Volumn 27, Issue 1, 2016, Pages 59-65

  Bagoly, Zsuzsa ^a   Homoródi, Nóra ^a   Kovács, Emese Gyöngyvér ^a   Sarkady, Ferenc ^a   Csiba, László ^a   Édes, István ^a   Muszbek, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Anti platelet drug; aspirin; clopidogrel; drug resistance; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR; THROMBOXANE B2; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; DRUG INTERACTION; DRUG MONITORING; PROCEDURES;

ASPIRIN; CASE-CONTROL STUDIES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84955366387     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2015.1031098     Document Type: Article

References (37)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054
2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-e122
3. Manolis AS, Manolis TA, Papadimitriou P, Koulouris S, Melita H. Combined antiplatelet therapy: Still a sweeping combination in cardiology. Cardiovasc Hematol Agents Med Chem 2013; 11: 136-167
4. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
5. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the clopidogrel in unstable angina to prevent recurrent events (cure) study. Circulation 2003; 108: 1682-1687
6. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621
7. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073-3076
8. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383
9. Patrono C. Antiplatelet therapy. In: Michelson AD, editor. Platelets. Academic Press: New York; 2012. pp 1337-1348
10. Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 2012; 33: 143-153
11. Cattaneo M. Mechanisms of variability in antiplatelet agents response. Thromb Res 2012; 130: S27-S28
12. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, Peterfy H, Kiss RG, Edes I, Muszbek L. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 2014; 133: 811-816
13. Ofosu FA. Appropriate assessment of the functional consequences of platelet cyclooxygenase-1 inhibition by aspirin in vivo. Thromb Res 2014; 133: 697-698
14. Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, Peterfy H, Kiss RG, Edes I, Muszbek L. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin: The lack of aspirin resistance among healthy individuals. Thromb Res 2014; 131: 320-324
15. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014; 141: 69-78
16. Shantsila E, Lip GY. Aspirin resistance or treatment non-compliance: Which is to blame for cardiovascular complications? J Transl Med 2008; 6: 47
17. Cattaneo M. The clinical relevance of response variability to antiplatelet therapy. Hematology Am Soc Hematol Educ Program 2011; 2011: 70-75
18. Cattaneo M. Response variability to clopidogrel: Is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost 2011; 10: 327-336
19. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273
20. Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S. Prevalence of poor biological response to clopidogrel: A systematic review. Thromb Haemost 2012; 107: 494-506
21. Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ 2012; 21: 12-21
22. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011; 106: 211-218
23. Sibbing D, Orban M, Massberg S. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome: Agents, indications, issues to consider in clinical practice. Hamostaseologie 2013; 33: 9-15
24. Gurbel PA, Tantry US. Clopidogrel response variability and the advent of personalised antiplatelet therapy: A bench to bedside journey. Thromb Haemost 2011; 106: 265-271
25. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933
26. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014; 35: 209-215
27. Aradi D, Sibbing D, Bonello L. Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. Int J Cardiol 2013; 167: 1794-1797
28. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5: 230-237
29. Bagoly Z, Sarkady F, Magyar T, Kappelmayer J, Pongracz E, Csiba L, Muszbek L. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. PLoS One 2013; 8: e69417
30. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92
31. Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J. Defining, establishing, and verifying reference intervals in the clinical laboratory: Approved guideline. 3rd edition. Clinical and Laboratory Standards Institute Document C28-A3, vol. 28; 2008
32. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin "Resistance". J Am Coll Cardiol 2009; 53: 667-677
33. Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol 2013; 13: 242-250
34. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603
35. Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP, Pare G, Johnston M, Eikelboom JW. Multiple daily doses of ASA overcome reduced platelet response to once-daily ASA after CABG: A pilot randomized controlled trial. J Thromb Haemost 2015; 13: 448-456
36. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002; 99: 193-198
37. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4: 638-647